Date: 2017-04-25
Type of information: Nomination
Compound:
Company: Amag Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 25, 2017, Amag Pharmaceuticals announced the appointment of Arpad Simon to the role of vice president of pharmacovigilance. Dr. Simon has worked in the pharmaceutical industry for more than 20 years with extensive operational and leadership experience in clinical development and pharmacovigilance. Prior to joining Amag, he served in executive-level pharmacovigilance roles at Relypsa, Mitsubishi Tanabe Pharma, Pfizer and other companies.
- Dr. Simon will have responsibility for all pharmacovigilance functions at AMAG, including product safety surveillance, aggregate safety reporting and risk management. He will also oversee safety evaluation across the company’s clinical development activities and marketed therapeutics.
- In addition to his roles in the pharmaceutical industry both from a U.S. and global perspective, Dr. Simon also worked for five years at the FDA Center for Drug Evaluation and Research. He has successfully led and managed initiatives in the areas of clinical trials, post-marketing safety, benefit-risk management, business development, integration, process design and regulatory interactions. Dr. Simon received his medical degree from Albert Szent-Gyorgyi Medical University in Hungary.
Financial terms:
Latest news:
Is general: Yes
